Stay updated with breaking news from Creation House Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Antibody-drug conjugates (ADC) are booming in the biotech industry this year with mounting investment and M&A deals. Here are five ADC players that have caught the eye of investors in the last 12 months.
“I like the excitement of not knowing what’s going to happen and I think I thrive on it.”For the first interview in our Human Strategy Series, the team recently spoke with Dr Jackie Ameri, CEO of Pancryos, who benefited from our Leadership Assessment service as part of the partnership between...
Share this article Share this article COPENHAGEN, Denmark, April 29, 2021 /PRNewswire/ -- Adcendo, a biotech company developing antibody-drug conjugates (ADCs) for the treatment of cancers, today announced the successful closing of a EUR 51 million (US$ 62 million) Series A financing. The investment was led by Novo Seeds, the early-stage investment and company creation team of Novo Holdings, and Ysios Capital, along with RA Capital Management, HealthCap and Gilde Healthcare. The company was initially incubated and funded at the BioInnovation Institute (BII). The new financing, which is th...
Novo Seeds co-leads Adcendo's EUR 51 Million Series A Financing to Advance Novel Antibody-Drug Conjugates for Treatment of Cancers - Novo Seeds played instrumental role in supporting Adcendo from inception - Plans to build a pipeline of ADCs directed at novel cancer targets COPENHAGEN, Denmark, April 29, 2021 /PRNewswire/ -- Novo Seeds, the early stage investment and company creation team of Novo Holdings, announced today an investment in Adcendo, a Danish biotech company which is developing antibody-drug conjugates (ADCs) for the treatment of cancers. The EUR 51 million (US$ 62 million) Ser...